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Abstract
The Central European Congress of Rheumatology
(CECR) has been organized by seven Central European
countries: Austria, Croatia, Czech Republic, Hungary,
Poland, Slovakia, and Slovenia. These countries have
lots of similarities, but also differences, with respect
to rheumatology research. In this paper, based on
questionnaires, we wish to demonstrate achievements
and difficulties in rheumatology research performed
in our region.
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Background
Central European countries have common geopolitical
backgrounds and numerous similarities with respect to
history and development including medical care and
research. Here we will deal with the seven official orga-
nizers of the Central-Eastern Congress of Rheumatology
(CECR): Austria, Croatia, Czech Republic, Hungary,
Poland, Slovakia, and Slovenia. There are significant
differences between the countries with respect to gross
domestic product (GDP), organization of healthcare,
and research funding.
In this brief review, we wish to describe the recent de-
velopments and present the current situation of clinical
rheumatology and research in Central Europe. For this
purpose, we sent out a questionnaire to the presidents of
the national societies.
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Some indicators of rheumatology care
In order to understand rheumatological research in these
countries, first we should assess postgraduate training and
the definition of rheumatologists. In some countries, such
as Austria and Czech Republic, most rheumatologists are
also internists. On the other hand, in Hungary, about 70%
of rheumatologists are not internists so many of them do
not treat connective tissue diseases.
There are between 2 and 75 rheumatology hospitals/
departments in these countries. Where internists treat
rheumatic patients, most outpatient and inpatient care
is of course performed in internal medicine units.
There are variable numbers of patients treated with
biologics (Table 1).
Description of rheumatology research
As seen in Table 1, significant research in the field of ar-
thritides, osteoporosis, and connective tissue diseases has
been carried out over the past years. Our rheumatologists
have been involved in the development of international
recommendations (e.g. management of rheumatoid
arthritis (RA), early RA, spondyloarthropathies, systemic
sclerosis, systemic lupus erythematosus (SLE), myositis,
Sjögren’s syndrome, polymyalgia rheumatica, vasculit-
ides, osteoporosis, alkaptonuria, cardiovascular comor-
bidities, and ultrasound) [1–13]. There have been active
members of EULAR, EUSTAR, GRAPPA, ASAS, EURO-
PHOSPHOLIPD, MYONET, and several other working
groups. Although there have been significant limitations
in funding of research, recently our countries have been
involved in large European Union (EU), Horizon2020,
Foreum, and other collaborative projects.
The Central European Congress of Rheumatology
CECR congresses started in 1996 in Piestany (Slovakia),
and were followed by meetings every other year in
Warsaw (1998), Bratislava (2000), Baden (2002),
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Budapest (2004), Bled (2006), Prague (2008), Sopron
(2010), Krakow (2012), Vienna (2014), and again
Prague (2016). Croatia joined “the club” in 2016 and
the next meeting will be in Zagreb in 2018.
EULAR activities
The 70-year-old European League Against Rheumatism
(EULAR) is the key organization in the field of rheuma-
tology. The seven countries have nominated country
representatives on the EULAR committees. In addition,
Frantisek Lenoch (Czechoslovakia), Karl Gotsch (Austria),
Béla Gömör (Hungary), and Josef Smolen (Austria)
served as EULAR presidents. Karel Pavelka (Czech
Republic) and László Czirják (Hungary) worked as
General Secretary. Tadej Avcin (Slovenia) is currently
Chairperson of the Standing Committee on Paediatric
Rheumatology. Daniel Aletaha (Austria) chaired the
Standing Committee for Clinical Affairs. Zoltan Szeka-
necz (Hungary) and Tadej Avcin are currently mem-
bers of the Scientific Programme Committee of the
EULAR congress. Past members of the Scientific Com-
mittee include Jiri Vencovsky and Karel Pavelka (Czech
Republic), Wlodzimierz Maslinski (Poland), and Kurt
Redlich (Austria). Jiri Vencovsky is currently acting as
the treasurer for FOREUM.
The numbers of submitted and accepted EULAR ab-
stracts are relevant indicators of the quality of rheuma-
tology research. As listed in Table 2, the 7 countries
together submitted 169, 152, 153, 133, and 138 ab-
stracts to the last five EULAR congresses (2012–2016),
respectively. The total number of submissions to these
congresses was 3806, 3872, 4041, 4323, and 4109, re-
spectively. Thus, our 7 countries submitted 4.4%, 3.9%,
3.8%, 3.1%, and 3.4% of all abstracts, respectively. The
percentage of accepted abstracts (oral + poster tour +
poster + abstract publication only) was 79.3%, 75.0%,
85.0%, 79.7%, and 77.5%, respectively.
With respect to the number of abstract submissions,
in 2015 Austria, Croatia, Czech Republic, Hungary,
Poland, Slovakia, and Slovenia ranked 36th, 48th, 35th,
30th, 27th, 51st, and 46th, respectively, among the 84
countries with abstract submissions. In 2016, these
ranks were 29th, 53rd, 32nd, 35th, 28th, 62nd, and 45th, re-
spectively. Austria, Croatia, Czech Republic, Hungary,
Poland, Slovakia, and Slovenia submitted 150, 40, 138,
150, 190, 34, and 43 abstracts, respectively, a total of
745, to the 2012–2016 congresses. The total acceptance
rates were 88.0%, 77.5%, 77.5%, 72.7%, 81.6%, 55.9%,
and 88.4%, respectively. Austria (n = 7), Hungary (n = 6),
Poland (n = 6), and Czech Republic (n = 5) had the most
oral presentations.
The seven countries have varying population numbers
(Table 1) so their relative share within the whole of
Europe differs. However, the seven Central European
countries took a significant share (3–4%) of abstracts
submissions to recent EULAR congresses with an ac-
ceptance rate of 75–85%.
EWRR
The first European Workshop of Rheumatology Research
(EWRR) was organized in London in 1981. The idea of
the annual EWRR meetings was to give a platform to
mostly young researchers to present their data in basic
and translational rheumatology research. To date, 37
EWRR meetings have been organized. Among our seven
countries, Vienna (twice), Warsaw, Prague, and Budapest
have hosted EWRR congresses. An also increasing
number of presentations from Central Europe has been
included in the very recent EWRR meetings.
Problems to solve
Maybe with the exception of Austria, our countries have
experienced a significant delay in the development of
rheumatology research. For many years, only Austria
and Czech Republic could be part of large international
projects (e.g. BeTheCure, AutoCure). In many coun-
tries, research is very much centralized to the capital
(Vienna, Prague, Ljubljana, Zagreb) or to nominated
centres (Piestany). It is more evenly distributed among
numerous university towns in Hungary and Poland. A
major problem is lack of interest of young physicians in
the field of rheumatology, as well as the large workload
in routine clinical practice, leaving little time for re-
search. With the advent of new therapies and novel
molecular insights, this interest will hopefully rise again
over the next years. Funding has been an issue and we
hope that, with development, these countries could also
participate in more EU- or EULAR-related projects.
With respect to human resources, the "next generation"
of rheumatologists is now slowly establishing itself in
the international community.
Conclusion
Although, with the exception of Austria, these countries
were socialist countries, significant development has
been observed in rheumatology research.
Table 2 EULAR congress activity
2012 2013 2014 2015 2016 Total
Submitted 169 152 153 133 138 745
Accepted 134 114 130 106 107 591
Oral 5 2 9 5 5 26
Poster tour 9 17 7 9 12 54
Poster 42 55 38 45 43 223
Publication 78 40 76 47 47 288
Acceptance rate (%) 79.3 75.0 85.0 79.7 77.5 79.3
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